Hepatitis C and Nonalcoholic Fatty Liver Disease

Seela Ramesh; Arun J. Sanyal

doi:10.1055/s-2004-860869

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2004; 24(4): 399-413
DOI: 10.1055/s-2004-860869

Hepatitis C and Nonalcoholic Fatty Liver Disease

Seela Ramesh¹ , Arun J. Sanyal¹ ^, ²

¹Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia
²Professor of Medicine

Abstract

ABSTRACT

Hepatitis C virus (HCV) and nonalcoholic fatty liver disease (NAFLD) are the two most common causes of chronic liver disease in North America. NAFLD represents a spectrum of liver lesions that occur in individuals who either do not consume any alcohol or only consume alcohol in quantities generally considered not to be harmful to the liver. This spectrum consists of isolated hepatic macrovesicular steatosis at one end and nonalcoholic steatohepatitis (NASH) at the other. Hepatic steatosis is present in ∼50% of the subjects with HCV. Genotype 3 is independently associated with hepatic steatosis. In those with genotype 1 infection, steatosis is associated with features of the metabolic syndrome. The presence of hepatic steatosis correlates with the stage of hepatic fibrosis in patients with HCV. This has been related to the presence of insulin resistance. Hepatic steatosis also adversely affects the virologic response rates to anti-HCV therapy. In this article, we will review the epidemiology of HCV and NAFLD, their impact on each other, and the course of the liver disease in individuals afflicted with both conditions.

KEYWORDS

Hepatitis C - nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - fatty liver - metabolic syndrome - insulin resistance - hepatic fibrosis - cirrhosis - virologic response

Full Text

References

REFERENCES

1 Sandler R S, Everhart J E, Donowitz M et al.. The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122 1500-1511
2 Alter M J, Kruszon-Moran D, Nainan O V et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341 556-562
3 Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep. 2004; 6 66-70
4 Lonardo A, Adinolfi L E, Loria P, Carulli N, Ruggiero G, Day C P. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004; 126 586-597
5 Monto A, Alonzo J, Watson J J, Grunfeld C, Wright T L. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002; 36 729-736
6 Sanyal A J, Contos M J, Sterling R K et al.. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol. 2003; 98 2064-2071
7 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55 434-438
8 Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994; 107 1103-1109
9 Byron D, Minuk G Y. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology. 1996; 24 813-815
10 Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn. 1992; 27 521-528
11 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12 1106-1110
12 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98 960-967
13 Galambos J T, Wills C E. Relationship between 505 paired liver tests and biopsies in 242 obese patients. Gastroenterology. 1978; 74 1191-1195
14 Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med. 1988; 27 142-149
15 Nomura F, Ohnishi K, Satomura Y et al.. Liver function in moderate obesity-study in 534 moderately obese subjects among, 4613 male company employees. Int J Obes. 1986; 10 349-354
16 Bellentani S, Saccoccio G, Masutti F et al.. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132 112-117
17 Tominaga K, Kurata J H, Chen Y K et al.. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci. 1995; 40 2002-2009
18 Hedley A A, Ogden C L, Johnson C L, Carroll M D, Curtin L R, Flegal K M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004; 291 2847-2850
19 Clouston A D, Powell E E. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002; 16 767-781
20 Hwang S J, Luo J C, Chu C W et al.. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001; 16 190-195
21 Fiore G, Fera G, Napoli N, Vella F, Schiraldi O. Liver steatosis and chronic hepatitis C: a spurious association?. Eur J Gastroenterol Hepatol. 1996; 8 125-129
22 Rogers D W, Lee C H, Pound D C, Kumar S, Cummings O W, Lumeng L. Hepatitis C virus does not cause nonalcoholic steatohepatitis. Dig Dis Sci. 1992; 37 1644-1647
23 Hallsten K, Yki-Jarvinen H, Peltoniemi P et al.. Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. Obes Res. 2003; 11 257-265
24 Anthonsen M W, Ronnstrand L, Wernstedt C, Degerman E, Holm C. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem. 1998; 273 215-221
25 Marchesini G, Bugianesi E, Forlani G et al.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37 917-923
26 Bergman R N. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res. 1997; 52 359-385
27 Hube F, Hauner H. The two tumor necrosis factor receptors mediate opposite effects on differentiation and glucose metabolism in human adipocytes in primary culture. Endocrinology. 2000; 141 2582-2588
28 Diez J J, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003; 148 293-300
29 Goodpaster B H, Thaete F L, Simoneau J A, Kelley D E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997; 46 1579-1585
30 Maeda N, Funahashi T. Adiponectin knockout mice. Nippon Rinsho. 2004; 62 1067-1076
31 Kamada Y, Tamura S, Kiso S et al.. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003; 125 1796-1807
32 Song Z, Joshi-Barve S, Barve S, McClain C J. Advances in alcoholic liver disease. Curr Gastroenterol Rep. 2004; 6 71-76
33 Morange P E, Alessi M C, Juhan-Vague I. Relations between hemostatic variables, insulin resistance and inflammation. Hematol J. 2004; 5(suppl 3) S15-S19
34 Dhindsa G, Bhatia R, Dhindsa M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med. 2004; 50 140-144
35 Sjoholm A, Nystrom T. Chronic inflammation can cause type 2 diabetes. Lakartidningen. 2004; 101 1716-1721
36 Dandona P. The link between insulin resistance syndrome and inflammatory markers. Endocr Pract. 2003; 9(suppl 2) 53-57
37 Uwaifo G I, Ratner R E. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med. 2003; 115(suppl 8A) 12S-19S
38 Nishimura F, Iwamoto Y, Mineshiba J, Shimizu A, Soga Y, Murayama Y. Periodontal disease and diabetes mellitus: the role of tumor necrosis factor-alpha in a 2-way relationship. J Periodontol. 2003; 74 97-102
39 Nishimura F, Murayama Y. Periodontal inflammation and insulin resistance-lessons from obesity. J Dent Res. 2001; 80 1690-1694
40 Svenson K L, Lundqvist G, Wide L, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism. 1987; 36 940-943
41 Ma L J, Marcantoni C, Linton M F, Fazio S, Fogo A B. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001; 59 1899-1910
42 Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy R P, Haffner S M. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int. 2000; 58 1703-1710
43 Hui J M, Sud A, Farrell G C et al.. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003; 125 1695-1704
44 Bahtiyar G, Shin J J, Aytaman A, Sowers J R, McFarlane S I. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep. 2004; 4 194-198
45 Petit J M, Bour J B, Galland-Jos C et al.. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001; 35 279-283
46 Lopez-Bermejo A, Botas P, Funahashi T et al.. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf). 2004; 60 256-263
47 Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology. 2004; 40 46-54
48 Carmichael A R, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004; 13 85-92
49 Regimbeau J M, Colombat M, Mognol P et al.. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004; 10(suppl 1) S69-S73
50 Giovannucci E. Obesity, gender, and colon cancer. Gut. 2002; 51 147
51 Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg. 2003; 27 999-1008
52 Kazama Y, Noguchi T, Kanemaru Y, Wakasugi M, Onaya T, Yoshida Y. Effect of insulin on the production of prostacyclin and cell proliferation in cultured smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids. 1989; 37 129-134
53 Onuma M, Bub J D, Rummel T L, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem. 2003; 278 42660-42667
54 El Serag H B, Richardson P A, Everhart J E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol. 2001; 96 2462-2467
55 Sanyal A J. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123 1705-1725
56 Randle P J, Garland P B, Hales C N, Newsholme E A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; 1 785-789
57 Haque M, Sanyal A J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2002; 16 709-731
58 Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003; 29 478-485
59 Tarling E, Salter A, Bennett A. Transcriptional regulation of human SREBP-1c (sterol-regulatory-element-binding protein-1c): a key regulator of lipogenesis. Biochem Soc Trans. 2004; 32(Pt 1) 107-109
60 Mingrone G, Rosa G, Greco A V et al.. Intramyocitic lipid accumulation and SREBP-1c expression are related to insulin resistance and cardiovascular risk in morbid obesity. Atherosclerosis. 2003; 170 155-161
61 Shimano H. Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm. 2002; 65 167-194
62 Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair K S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002; 35 898-904
63 Banner B F, Savas L, Zivny J, Tortorelli K, Bonkovsky H L. Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. Am J Clin Pathol. 2000; 114 860-866
64 Paraschiv C, Graur M, Butnariu G, Mihai B, Constantinescu D. The pathological mechanisms of glycoregulation disturbances in chronic hepatitis B and C [in Romanian]. Rev Med Chir Soc Med Nat Iasi. 2002; 107 294-297
65 Lu S M, Song S M, Liu J C, Yang H M, Li P, Wang Z G. Changes of proton transportation across the inner mitochondrial membrane and H(+)-ATPase in endotoxic shock rats. Chin J Traumatol. 2003; 6 292-296
66 Marchesini G, Brizi M, Morselli-Labate A M et al.. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107 450-455
67 Day C P. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?. Gut. 2002; 50 585-588
68 Reid A E. Nonalcoholic steatohepatitis. Gastroenterology. 2001; 121 710-723
69 Caldwell S H, Swerdlow R H, Khan E M et al.. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999; 31 430-434
70 Angulo P, Lindor K D. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology. 2001; 120 1281-1285
71 Sanyal A J, Campbell-Sargent C, Mirshahi F et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120 1183-1192
72 Berson A, De B V, Letteron P et al.. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998; 114 764-774
73 Weltman M D, Farrell G C, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998; 27 128-133
74 Weltman M D, Farrell G C, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996; 111 1645-1653
75 Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994; 107 1103-1109
76 George D K, Goldwurm S, MacDonald G A et al.. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998; 114 311-318
77 Bonkovsky H L, Jawaid Q, Tortorelli K et al.. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999; 31 421-429
78 Younossi Z M, Gramlich T, Bacon B R et al.. Hepatic iron and nonalcoholic fatty liver disease. Hepatology. 1999; 30 847-850
79 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30 1356-1362
80 Guillygomarc'h A, Mendler M H, Moirand R et al.. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol. 2001; 35 344-349
81 Rouault T A. Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis?. Alcohol. 2003; 30 103-106
82 Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep. 2003; 5 18-25
83 Contos M J, Sanyal A J. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol. 2002; 9 37-51
84 Monto A, Alonzo J, Watson J J, Grunfeld C, Wright T L. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002; 36 729-736
85 Sharma P, Balan V, Hernandez J et al.. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?. Dig Dis Sci. 2004; 49 25-29
86 Castera L, Hezode C, Roudot-Thoraval F et al.. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004; 53 420-424
87 Rubbia-Brandt L, Fabris P, Paganin S et al.. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004; 53 406-412
88 Adinolfi L E, Utili R, Andreana A et al.. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci. 2001; 46 1677-1683
89 Adinolfi L E, Andreana A, Utili R, Zampino R, Ragone E, Ruggiero G. HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Am J Gastroenterol. 1998; 93 2162-2166
90 Shintani Y, Fujie H, Miyoshi H et al.. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004; 126 840-848
91 Zhang W, Yue B, Wang G Q, Lu S L. Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis. Hepatobiliary Pancreat Dis Int. 2002; 1 577-580
92 Janssen H L, Higuchi H, Abdulkarim A, Gores G J. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol. 2003; 39 414-420
93 Realdon S, Pontisso P, Adami F et al.. High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. J Hepatol. 2001; 34 723-729
94 Kallinowski B, Haseroth K, Marinos G et al.. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 1998; 111 269-277
95 Perlemuter G, Sabile A, Letteron P et al.. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002; 16 185-194
96 Ong J P, Younossi Z M, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001; 21 266-271
97 Friedenberg F, Pungpapong S, Zaeri N, Braitman L E. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab. 2003; 5 150-155
98 Wang C S, Wang S T, Yao W J, Chang T T, Chou P. Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol. 2003; 158 1154-1160
99 Cholet F, Nousbaum J B, Richecoeur M et al.. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol. 2004; 28 272-278
100 Hickman I J, Clouston A D, MacDonald G A et al.. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002; 51 89-94
101 Paradis V, Mathurin P, Kollinger M et al.. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol. 1997; 50 401-406
102 Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1997; 113 1069-1073
103 Okuda M, Li K, Beard M R et al.. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002; 122 366-375
104 Maeno T, Okumura A, Ishikawa T et al.. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2003; 18 1358-1363
105 Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979; 67 811-816
106 Silverman J F, O'Brien K F, Long S et al.. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990; 85 1349-1355
107 Teoh N C, Farrell G C. Management of chronic hepatitis C virus infection: a new era of disease control. Intern Med J. 2004; 34 324-337
108 Lam N P, DeGuzman L J, Pitrak D, Layden T J. Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection. Dig Dis Sci. 1994; 39 2660-2664
109 Giannini E, Ceppa P, Botta F et al.. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver. 1999; 19 432-437
110 Czaja A J, Carpenter H A, Santrach P J, Moore S B. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998; 29 198-206
111 Wong V S, Wight D G, Palmer C R, Alexander G J. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. J Clin Pathol. 1996; 49 465-469
112 Hourigan L F, MacDonald G A, Purdie D et al.. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999; 29 1215-1219
113 Rubbia-Brandt L, Leandro G, Spahr L et al.. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology. 2001; 39 119-124
114 Adinolfi L E, Gambardella M, Andreana A, Tripodi M F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001; 33 1358-1364
115 Sharma P, Balan V, Hernandez J et al.. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?. Dig Dis Sci. 2004; 49 25-29
116 Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002; 37 837-842
117 Castera L, Hezode C, Roudot-Thoraval F et al.. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003; 52 288-292

Arun J SanyalM.D.

Professor of Medicine, Pharmacology and Pathology

MCV Box 980341, Richmond

VA 23298-0341

Email: ajsanyal@hsc.vcu.edu